By Michele Maatouk
Date: Tuesday 07 Apr 2026
(Sharecast News) - California-based Gilead Sciences said on Tuesday that it has agreed to buy German clinical stage biotechnology group Tubulis for up to $5bn.
By Abigail Townsend
Date: Monday 23 Feb 2026
(Sharecast News) - Shares in Arcellx soared on Monday, after the US biotech agreed to be taken over by Gilead Sciences in a near $8bn deal.
By Frank Prenesti
Date: Thursday 23 Feb 2023
(Sharecast News) - UK pharma firm GSK's HIV treatment division, ViiV Healthcare, said its HIV injection treatment was as effective as a daily pill made by Gilead Sciences.
| Currency | US Dollars |
| Share Price | $ 131.65 |
| Change Today | $ 0.81 |
| % Change | 0.62 % |
| 52 Week High | $155.80 |
| 52 Week Low | $97.07 |
| Volume | 5,517,169 |
| Shares Issued | 1,241.00m |
| Market Cap | $163,378m |
| Beta | 0.01 |
| RiskGrade | 120 |
| Strong Buy | 10 |
| Buy | 13 |
| Neutral | 5 |
| Sell | 1 |
| Strong Sell | 0 |
| Total | 29 |

| Time | Volume / Share Price |
| 15:59 | 100 @ $131.63 |
| 15:59 | 200 @ $131.65 |
| 15:59 | 700 @ $131.65 |
| 15:59 | 600 @ $131.64 |
| 15:59 | 100 @ $131.63 |
You are here: research